NCT07397611 2026-03-20Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer InstitutePhase 2 Recruiting32 enrolled
NCT03629756 2024-05-24A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesArcus Biosciences, Inc.Phase 1 Completed48 enrolled